Personalized medicine in gastric cancer: Where are we and where are we going?

doi:10.3748/wjg.v22.i3.1160

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12673)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

997

WORD

406

HTML

7146

Figures (1-2)

318

Tables (1-1)

226

Sum=9093

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

423

Download

797

Sum=1220

Publishing Process of This Article

Item

Count

Browse

938

Download

1422

Sum=2360

Jan 21, 2016 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (38)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jan 21, 2016; 22(3): 1160-1171
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1160

Full Size Figure Download Figure

Figure 2 Proportion of genetic abnormalities in distinct gastric cancer subtypes. EBV: Epstein-Barr-positive; MSI: Microsatellite-instability; GS: Genomically stable; CIN: Chromosomal instability; PIK3CA/AKT: Phosphatidylinositol 3-kinase CA/AKT; HER2: Human epidermal growth factor receptor 2; HER3: Human epidermal growth factor receptor 3; FGFR2: Fibroblast growth factor receptor 2; KRAS: Kirsten rat sarcoma oncogene; MET: Mesenchymal-epithelial transition; JAK2: Janus kinase 2; PD-1/PD-L1: Programmed cell death-1/programmed cell death-ligand 1.

Citation: Jácome AA, Coutinho AK, Lima EM, Andrade AC, Santos JSD. Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol 2016; 22(3): 1160-1171
URL: https://www.wjgnet.com/1007-9327/full/v22/i3/1160.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i3.1160